Vitamin B3 (niacinamide)

Vitamin B3 (Niacinamide / Nicotinamide): A Comprehensive Reference

1. Identity, Chemical Nomenclature, and Common Forms

Niacin (also known as vitamin B3) is one of the water-soluble B vitamins. Niacin is the generic name for nicotinic acid (pyridine-3-carboxylic acid), nicotinamide (niacinamide or pyridine-3-carboxamide), and related derivatives, such as nicotinamide riboside. The IUPAC name of niacinamide is 3-pyridinecarboxamide, and its CAS registry number is 98-92-0. Niacinamide is a small molecule with an understated elegance: a pyridine ring with a carboxamide group, it belongs to the family of B vitamins. It dissolves easily in water, resists breakdown in heat, and holds its own in diverse environments.

The two most common forms of niacin in food and supplements are nicotinic acid and nicotinamide. While both forms are classed as vitamin B3, they are chemically distinct: nicotinic acid (niacin) may be used for treating deficiency, but nicotinamide has the benefit of not causing skin flushing. Niacin (nicotinic acid) and niacinamide, while both labeled as vitamin B3, also have different applications. Niacinamide is useful in arthritis and early-onset type 1 diabetes while niacin is an effective reducer of high cholesterol levels.

Niacin is naturally present in many foods, added to some food products, and available as a dietary supplement. Niacin is available in multivitamin/mineral products, in supplements containing other B-complex vitamins, and in supplements containing niacin only. Topical preparations (creams, gels, and serums at concentrations commonly ranging from 2% to 5%) are also widely used in dermatology and cosmetic formulations.

2. Natural Sources

Dietary sources of niacin include liver, red meat, fish, poultry, legumes, and whole-grain or enriched cereals and breads. Because dietary tryptophan can be metabolized to niacin, foods rich in tryptophan (e.g., dairy products) can compensate for inadequate dietary niacin. The body can also convert tryptophan—an amino acid—to nicotinamide.

Niacin in mature cereal grains is largely bound and thus is only about 30 percent available; alkali treatment of the grain increases the percentage absorbed. Niacin in the coenzyme NAD/NADP form in meats appears to be much more available. Niacin added during enrichment or fortification is in the free form and thus highly available.

An important historical and epidemiological note concerns maize (corn): corn is naturally high in niacin, but it is bound to carbohydrates which makes it difficult for the human body to absorb. However, when corn is nixtamalized (a traditional process in tortilla making where corn is treated with calcium hydroxide, cooked, and ground) the niacin becomes absorbable because of the calcium hydroxide treatment.

3. Historical and Traditional Use

The discovery of the role of niacin is closely linked with the story of pellagra. This disease was widespread throughout human history, especially among impoverished people whose diet consisted almost entirely of corn products. Pellagra was initially described by the physician Gaspar Casal in Spain in 1735, soon after maize was introduced into Europe. The name of the disease was established in 1771 by an Italian physician Francesco Frapolli.

Due to the great increase in the use of maize in northern Italy, pellagra became so widespread that a special hospital (known as Legano) was built in 1784 exclusively for pellagra patients. Reports on the occurrence of pellagra appeared soon thereafter in France (1829), Romania (1858), and Egypt (1874).

Historical data from Calcutta in 1935 documented pellagra in poor Hindu widows, emphasizing the role of dietary and social deprivation. In South Africa, pellagra remained a public health concern into the late 20th century, particularly among maize-dependent populations. A 2019 scoping review identified 15 major pellagra outbreaks from 1897 to 2019.

In Central and South America, the traditional method for making corn tortillas involves soaking the corn in limewater overnight. This process unbinds the niacin in the corn and makes it available to absorb. For this reason, pellagra has rarely been seen in these populations.

The scientific identification of niacin as the curative agent came in the 20th century. In 1915, Goldberger conducted a series of experiments on 11 healthy volunteer prisoners in a Mississippi jail and found that he could induce pellagra by altering their diets. He concluded that the disease was caused by the absence of some factor lacking in corn, but that could be found in meat and milk. He named it the P-P (for pellagra-preventative) factor. The chemical structure of that factor was subsequently discovered in 1937 by the American biochemist Conrad Arnold Elvehjem. He induced a black tongue in dogs by feeding them the Goldberger diet, and then cured the disease by supplementing their diet with nicotinic acid. In 1937, Elvehjem isolated two key compounds from liver extracts: nicotinic acid and its amide form, niacinamide. He demonstrated that both could cure "black tongue" disease in dogs—a model for human pellagra.

The following decade, American biochemist Conrad A. Elvehjem discovered that the missing nutrient was niacin. By mid-century, bread and cereal products in the United States were routinely fortified with niacin, a practice that continues today. Soon after its discovery, nicotinamide became the preferred form of vitamin B3 for nutritional supplementation and food fortification, largely because it does not cause the flushing reaction commonly associated with niacin intake.

4. Key Constituents and Active Compounds

Niacinamide (nicotinamide) is itself the bioactive compound. Its principal physiological significance derives from its role as a precursor to two critical coenzymes:

• Nicotinamide adenine dinucleotide (NAD⁺/NADH): All tissues in the body convert absorbed niacin into its main metabolically active form, the coenzyme nicotinamide adenine dinucleotide (NAD). More than 400 enzymes require NAD to catalyze reactions in the body, which is more than for any other vitamin-derived coenzyme.
• Nicotinamide adenine dinucleotide phosphate (NADP⁺/NADPH): NAD is also converted into another active form, the coenzyme nicotinamide adenine dinucleotide phosphate (NADP), in all tissues except skeletal muscle. NAD and NADP are required in most metabolic redox processes in cells where substrates are oxidized or reduced.

Niacin helps to convert nutrients into energy, create cholesterol and fats, create and repair DNA, and exert antioxidant effects.

Niacin, a component of coenzymes, is used in oxidation and reduction reactions essential for cellular metabolism. It is involved in the cellular processing of proteins, carbohydrates, and fats. Tissues with high regeneration rates and high energy consumption, such as the skin, intestines, and brain, can be particularly affected by niacin deficiency.

5. Mechanisms of Action

5.1 NAD⁺ Metabolism and Energy Production

As a precursor to nicotinamide adenine dinucleotide (NAD⁺), essential for ATP production and a substrate for poly-ADP-ribose polymerase-1 (PARP-1), niacinamide plays roles in DNA repair, cellular stress mechanisms, and anti-aging benefits.

5.2 PARP Enzyme System and DNA Repair

The poly(ADP-ribose) polymerase (PARP) family consists of 18 genes, which encode 17 enzymes with either mono-ADP ribosyltransferase or PARP activity. NAD⁺ is used as a substrate for mono-ADP-ribosylation of target proteins and for poly(ADP-ribose) polymerization catalyzed by PARP activity. Nicotinamide is released as a by-product. Hydrolysis of mono- and poly-ADP-ribosylated proteins results in the production of ADP-ribose. These reversible processes are involved in DNA repair, apoptosis, and many other biological processes to maintain cellular homeostasis.

NAD is the sole substrate for PARP enzymes and sirtuins involved in DNA repair activities; thus, NAD is critical for genome stability.

5.3 Sirtuin (SIRT) Signaling

Sirtuins are a family of signaling proteins that have a mono-ADP-ribosyltransferase activity or a protein deacylase activity (deacetylase, desuccinylase, demalonylase, demyristoylase, or depalmitoylase activity) and have been hypothesized to play a role in the aging process. Sirtuins are NAD⁺-dependent enzymes that have protein deacetylase and ADP-ribosyltransferase activities that upregulate stress response pathways.

Controlling cellular NAD⁺ via niacin restriction demonstrates a hypersensitivity to photodamage that involves specific PARPs and SIRTs and accumulation of acetylated proteins, all of which are reversed by niacin repletion. These data show that niacin functions through NAD⁺-dependent photodamage response pathways that limit skin photodamage and thus, ultimately, skin cancer.

5.4 Inhibition of Melanosome Transfer (Skin Pigmentation)

Niacinamide had no effect on the catalytic activity of mushroom tyrosinase or on melanogenesis in cultured melanocytes. However, niacinamide gave 35–68% inhibition of melanosome transfer in a coculture model and reduced cutaneous pigmentation. This mechanism—acting on the transfer of melanosomes from melanocytes to keratinocytes rather than on melanin synthesis itself—is considered a primary basis for its skin-lightening effects.

5.5 Photoprotection and UV Defense

Nicotinamide prevents ultraviolet radiation (UV) from reducing ATP levels and inhibiting glycolysis, thus preventing the UV radiation-induced energy crisis. This enhances DNA repair and reduces UV-induced suppression of immunity. Nicotinamide rescued the viability of a Chinese hamster ovary cell line irradiated with UV radiation and prevented apoptosis through mechanisms related to the stabilization of cytoskeleton proteins. Nicotinamide also exhibited a protective effect against UVA- and/or UVB-induced DNA damage in normal human epidermal melanocytes, as indicated by decreased levels of cyclobutane pyrimidine dimers and 8-hydroxy-2'-deoxyguanosine.

5.6 Intestinal Phosphate Transport Inhibition

Niacinamide inhibits intestinal sodium/phosphorus transporters and reduces serum phosphorus in open-label studies. This mechanism is particularly relevant to its studied use in hemodialysis patients with hyperphosphatemia.

6. Scientific Evidence by Area of Use

6.1 Pellagra (Niacin Deficiency Disease) — Strong Evidence

A disease caused by niacin deficiency is pellagra. Niacinamide prescription products are US FDA-approved for preventing and treating pellagra. It is sometimes preferred over niacin because it doesn't cause flushing, a side effect of niacin treatment. Nicotinamide doses of 250 to 500 mg/day orally are recommended. Despite nicotinic acid being the more common form of niacin, nicotinamide is used for niacin deficiencies as it does not cause symptoms such as tingling sensation, itching, or flushing.

In a recent case report, treatment with nicotinamide and B-vitamin supplementation led to rapid and sustained resolution of all symptoms in a pellagra patient who had followed a restrictive ketogenic diet over several years. The evidence supporting niacinamide for the treatment and prevention of pellagra is strong, based on historical clinical observation, pharmacological mechanism, and regulatory approval.

6.2 Skin: Hyperpigmentation and Photoaging — Moderate to Good Evidence

Multiple randomized clinical trials have evaluated topical niacinamide for skin hyperpigmentation. In double-blind, placebo-controlled, split-face, left–right, randomized clinical studies, Bissett et al. assessed the effect of nicotinamide on the appearance of aging facial skin. A moisturizer product with or without 5% nicotinamide was applied on the facial skin for 12 weeks. Nicotinamide at 5% was evaluated to be well tolerated by the skin and to improve a broad array of skin appearance measures (fine lines/wrinkles, texture, hyperpigmentation spots, red blotchiness, and skin sallowness), and elasticity.

In a randomized, split-face, double-blind, paired clinical study involving eighteen Japanese women with multiple types of brown hyperpigmentation, subjects applied a test moisturizer containing 5% nicotinamide and the control moisturizer without nicotinamide to each side of the face twice daily for 8 weeks. The side of the face receiving the test moisturizer showed a significant decrease in the total hyperpigmented area measured by image analysis and a reduction in visually assessed hyperpigmentation degree, compared to the side receiving the control moisturizer after 4 weeks or 8 weeks of treatment.

Niacinamide reduces oxidative stress, erythema, sallowness, and hyperpigmentation through inhibition of melanosome transfer, while randomized controlled trials have demonstrated improvement for fine lines, wrinkles, and the general appearance of skin.

6.3 Skin: Acne Vulgaris — Moderate Evidence

In acne vulgaris, sebum production is lowered, inflammatory calming effects are realized, and antimicrobial effects are seen, with the added advantage of boosting the hydration of the skin. A double-blinded randomized clinical trial (Shahmoradi et al., 2013) compared topical 5% nicotinamide gel versus 2% clindamycin gel in the treatment of mild-to-moderate acne vulgaris, providing comparative clinical evidence. Applying a cream containing niacinamide seems to improve the appearance of skin in people with acne. Evidence is moderate, based on a number of controlled trials, though effect sizes and comparators vary across studies.

6.4 Skin: Non-Melanoma Skin Cancer Chemoprevention — Mixed Evidence

This area has the most substantial and discussed body of evidence. In 2015, the seminal ONTRAC phase 3 randomized placebo-controlled clinical trial showed a 23% reduction in new non-melanoma skin cancers (NMSCs) among 386 immunocompetent adults who received either 500 mg of oral nicotinamide twice daily or placebo for 12 months.

More specifically, the 2015 phase 3 trial by Chen et al. of 386 high-risk immunocompetent patients demonstrated that oral nicotinamide (500 mg twice daily for 12 months) significantly reduced the rate of new NMSCs by 23% (P = 0.02) compared to placebo. Reductions were observed for new squamous cell carcinomas (30% reduction, P = 0.05) and basal cell carcinomas (20% reduction, P = 0.12), and actinic keratoses counts were significantly lower throughout treatment.

No noteworthy between-group differences were found with respect to the number or types of adverse events during the 12-month intervention period, and there was no evidence of benefit after nicotinamide was discontinued. Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.

However, subsequent trials yielded conflicting results: this study was met with significant criticism over its results, with one commentary calculating that the true effect of nicotinamide in this trial was likely overrepresented with a high statistical probability of non-reproducible results. In 2023, the subsequent ONTRANS phase 3 randomized placebo-controlled clinical trial observed no significant difference in prevention of keratinocyte cancers among 158 immunosuppressed solid-organ transplant recipient patients who similarly received either 500 mg of oral nicotinamide or placebo twice daily for 12 months. Over 6 months, a pilot trial in renal transplant patients by Chen et al. showed a nonsignificant 35% relative reduction in NMSC rate (P = 0.36) and a 16% reduction in AKs (P = 0.15) compared to placebo.

Overall, the evidence for NMSC chemoprevention is mixed: positive results in immunocompetent high-risk individuals and null results in immunosuppressed transplant recipients. The mechanism—prevention of UV-induced energy depletion and immune suppression—is biologically plausible, but generalizability across patient populations remains unresolved.

6.5 Hyperphosphatemia in Hemodialysis Patients — Moderate Evidence

Niacinamide inhibits intestinal sodium/phosphorus transporters and reduces serum phosphorus. A prospective, randomized, double-blind, placebo-controlled crossover trial was performed for assessment of the safety and efficacy of niacinamide. Hemodialysis patients with phosphorus levels ≥5.0 mg/dl were randomly assigned to 8 weeks of niacinamide or placebo, titrated from 500 to 1500 mg/d. Thirty-three patients successfully completed the trial. Serum phosphorus fell significantly from 6.26 to 5.47 mg/dl with niacinamide but not with placebo (5.85 to 5.98 mg/dl). In hemodialysis patients, niacinamide effectively reduces serum phosphorus when co-administered with binders and results in a potentially advantageous increase in HDL cholesterol.

A subsequent systematic review and meta-analysis confirmed these findings: nine relevant studies (n = 428) were included. Meta-analysis showed that levels of serum phosphorus (SMD −1.06; 95% CI, −1.27 to −0.85, P < .001), parathyroid hormone (SMD −1.09; 95% CI, −1.49 to −0.70, P < .001), and calcium–phosphorus product in the nicotinamide group were significantly lower than those of the control group. This represents a moderate level of evidence with consistent direction across studies, though studies are generally small.

6.6 Type 1 Diabetes Prevention and Beta-Cell Protection — Weak/Negative Evidence for Prevention

Nicotinamide prevents autoimmune diabetes in animal models, possibly through inhibition of the DNA repair enzyme poly-ADP-ribose polymerase and prevention of β-cell NAD depletion. This biological rationale motivated a large-scale human trial.

The landmark European Nicotinamide Diabetes Intervention Trial (ENDIT) was the definitive human investigation: a randomized double-blind placebo-controlled trial was conducted in 552 relatives with confirmed islet cell antibody levels of 20 JDF units or more. Participants were recruited from 18 European countries, Canada, and the USA, and were randomly allocated oral modified release nicotinamide (1.2 g/m²) or placebo for 5 years. The unadjusted hazard ratio for development of diabetes was 1.07 (95% CI 0.78–1.45; p = 0.69). Large-scale controlled trials of interventions designed to prevent the onset of type 1 diabetes are feasible, but nicotinamide was ineffective at the dose used.

In already-diagnosed patients, nicotinamide (NA), administered at diagnosis of the disease, can have beneficial effects on the clinical remission rate, improve metabolic control, and preserve or slightly increase beta-cell function, probably by reducing toxicity due to free radicals. However, larger controlled trial evidence for this benefit in established T1D is limited and the evidence base remains weak.

6.7 Osteoarthritis — Preliminary Evidence

To evaluate the effect of niacinamide on selected parameters of osteoarthritis, seventy-two patients with osteoarthritis were randomized for treatment with niacinamide or an identical placebo for 12 weeks. Outcome measures included global arthritis impact and pain, joint range of motion and flexibility, erythrocyte sedimentation rate, complete blood count, liver function tests, cholesterol, uric acid, and fasting blood sugar. Global arthritis impact improved by 29% (95% CI 6, 46) in subjects on niacinamide and worsened by 10% in placebo subjects (p = 0.04). In an earlier prospective, parallel group study comparing high-dose niacinamide (1500–4000 mg daily) in patients with OA with age-matched controls, enhanced joint range of motion, erythrocyte sedimentation rate, and overall arthritis severity within 2 months were described in those who received niacinamide. Evidence in this area is preliminary; the studies are small, and larger confirmatory trials are lacking.

6.8 Skin Barrier Function and Atopic Dermatitis — Emerging Evidence

Topical niacinamide adjuvants ceramides, free fatty acids, and cholesterol synthesis in keratinocytes to improve skin barrier, confirmed by randomized clinical trials. Due to its capacity to control sebum production, clinical investigations indicate advantages in acne and atopic dermatitis. Randomized controlled clinical trials have also shown that nicotinamide reduces transepidermal water loss and the development of new non-melanoma skin cancers in high-risk humans. This evidence is clinically useful but primarily drawn from smaller trials with mixed populations and formulations.

7. Body Systems and Health Areas

• Integumentary system (skin): Hyperpigmentation, photoaging, acne vulgaris, non-melanoma skin cancer chemoprevention, skin barrier integrity, atopic dermatitis.
• Metabolic/cellular energy: Niacin works in the body as a coenzyme, with more than 400 enzymes dependent on it for various reactions, including converting nutrients into energy, creating cholesterol and fats, creating and repairing DNA, and exerting antioxidant effects.
• Renal system: Hyperphosphatemia management in hemodialysis patients.
• Endocrine/pancreatic system: Investigated for beta-cell protection in type 1 diabetes.
• Musculoskeletal system: Osteoarthritis (preliminary).
• Nervous system and brain: Nicotinamide has been shown to provide systemic therapeutic benefits including anti-inflammatory effects, neuroprotection, and treatment of psychiatric disorders. These indications are largely investigational and lack robust human trial confirmation.

8. Recommended Dietary Allowances and Dosages Used in Studies

The Recommended Dietary Allowance (RDA) for adults is 16 mg/day of niacin equivalents (NEs) for men and 14 mg/day of NEs for women. The RDA for children ages 1 to 3 and 4 to 8 years of age is 6 and 8 mg/day of NE. For boys and girls ages 9 to 13, the RDA is 12 mg/day of NE. For individuals 14 years or older, the RDA is 16 and 14 mg/day of NE for males and females, respectively. The RDA during lactation is 17 mg/day of NE.

Dosages reported across clinical study areas:

• Pellagra treatment: Nicotinamide doses of 250 to 500 mg/day orally.
• Non-melanoma skin cancer chemoprevention (ONTRAC trial): 500 mg of oral nicotinamide twice daily for 12 months.
• Hemodialysis/hyperphosphatemia: Niacinamide titrated from 500 to 1500 mg/d.
• Type 1 diabetes prevention (ENDIT trial): Oral modified release nicotinamide at 1.2 g/m² body surface area for 5 years.
• Type 1 diabetes (residual beta-cell protection): 3 g/day of nicotinamide for nine months in one early double-blind study.
• Osteoarthritis: High-dose niacinamide 1500–4000 mg daily in a parallel group study.
• Topical skin formulations: 5% concentration is the most studied and most consistently effective topical dose for hyperpigmentation and antiaging outcomes; 2% nicotinamide-containing moisturizer efficacy did not show a statistically significant effect in at least one split-face study, while 5% did.

9. Safety Considerations and Drug Interactions

9.1 Tolerable Upper Intake Level and Adverse Effects

The Tolerable Upper Intake Level (UL) applies to niacinamide [nicotinamide]. Adverse effects such as nausea, vomiting, and signs and symptoms of liver toxicity have been observed at nicotinamide intakes of 3,000 mg/day. When taken by mouth, niacinamide is likely safe when used appropriately. Niacinamide-containing foods or supplements are safe when taken in doses lower than 35 mg daily. This 35 mg figure represents the UL for supplemental/added niacin for adults, as set by the Institute of Medicine, and applies to all forms including nicotinamide.

In contrast to nicotinic acid, nicotinamide has the benefit of not causing skin flushing. Flushing occurs mainly when taking high-dosage supplements in the form of nicotinic acid, rather than nicotinamide.

9.2 Hepatic Safety

Liver toxicity is a documented concern at very high doses. Impaired glucose tolerance and inflammation of the liver in severe cases occur at very high doses of 3,000–9,000 mg daily for several months/years. Hepatotoxicity at these levels is primarily documented with pharmacological nicotinic acid formulations, but the UL encompasses nicotinamide as well.

9.3 Absence of Lipid-Modifying and Statin-Interaction Effects

An important pharmacological distinction from nicotinic acid: niacin-induced myopathy is thought to occur through inhibition of the mevalonate pathway and drug-drug interactions involving CYP3A4 and OATP1B1 hepatic transport proteins. In contrast, nicotinamide has not been shown to affect the mevalonate pathway, as evidenced by its lack of lipid-lowering effects. Additionally, pharmacologic studies suggest that nicotinamide does not undergo hepatic uptake via the same transporters as niacin and therefore would not be expected to interact with pathways involved in statin metabolism.

9.4 Drug Interactions

Isoniazid and pyrazinamide: Isoniazid and pyrazinamide, used to treat tuberculosis, are structural analogs of niacin and interrupt the production of niacin from tryptophan by competing with a vitamin B6-dependent enzyme required for this process. In addition, isoniazid can interfere with niacin's conversion to NAD. Although pellagra can occur in patients with tuberculosis treated with isoniazid, it can be prevented with increased intakes of niacin. Supplementation with nicotinamide is specifically noted: for patients who receive isoniazid for TB prophylaxis, B complex multivitamin or nicotinamide supplementation should be considered to prevent niacin deficiency.

Estrogen-containing oral contraceptives: Estrogen and estrogen-containing oral contraceptives increase the efficiency of niacin synthesis from tryptophan, resulting in a decreased dietary requirement for niacin.

Chemotherapy agents: Long-term administration of chemotherapy agents has been reported to cause symptoms of pellagra; therefore, niacin supplementation may be needed.

Alcohol use: Treating patients with excess alcohol use who have multiple vitamin B deficiencies with a B complex containing insufficient amounts of niacin could aggravate the neurological clinical state or trigger the appearance of alcoholic pellagra encephalopathy.

Thrombocytopenia in hemodialysis: One clinical trial noted that oral nicotinamide, in addition to reducing serum phosphorus and increasing HDL, induces thrombocytopenia in hemodialysis patients, a specific adverse finding that requires monitoring in this population.

9.5 Sirtuin Inhibition Caveat

Similar to nicotinamide riboside, nicotinamide is an NAD⁺ precursor; however, in contrast to nicotinamide riboside, it is a direct inhibitor of SIRT1 activity, which may impede NAD⁺/SIRT1-derived effects on metabolism. This mechanistic consideration is relevant to researchers comparing niacinamide with other NAD⁺ precursors for metabolic or anti-aging purposes, though clinical significance in humans at typical supplemental doses remains to be fully established.

9.6 Pregnancy and Lactation

Niacin is likely safe when taken by mouth while pregnant and breastfeeding. The maximum recommended amount of niacin while pregnant or breastfeeding is 30 mg daily in those under 18 years of age, and 35 mg daily for those 19 years and older.

10. Current Regulatory and Pharmacopoeial Status

Niacinamide prescription products are US FDA-approved for preventing and treating pellagra. Beyond this nutritional indication, niacinamide is classified as a dietary supplement ingredient in the United States, as a food additive for fortification purposes, and as an active cosmetic ingredient in topical formulations globally. Its status as a recognized essential nutrient means it appears in major pharmacopoeias and is listed in the Dietary Reference Intakes framework of the National Academies of Sciences, Engineering, and Medicine.

References

• NIH Office of Dietary Supplements — Niacin: Health Professional Fact Sheet
• National Academies Press / NCBI Bookshelf — Dietary Reference Intakes for Niacin (Institute of Medicine, 1998)
• StatPearls (NCBI Bookshelf) — Niacin Deficiency
• Linus Pauling Institute, Oregon State University — Niacin Micronutrient Information Center
• Harvard T.H. Chan School of Public Health — The Nutrition Source: Niacin – Vitamin B3
• Merck Manual Professional Edition — Niacin Deficiency
• Cleveland Clinic — Pellagra: Definition, Symptoms & Treatment
• News-Medical.net — Niacin History
• PubMed — The discovery of niacin, biotin, and pantothenic acid (2012)
• PMC — Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation (2021)
• PubMed — The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer (2002)
• PLOS ONE — Effects of Niacin Restriction on Sirtuin and PARP Responses to Photodamage in Human Skin (2012)
• PubMed — A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention (ONTRAC, 2015)
• JAAD Reviews — Examining the safety of nicotinamide for skin cancer prevention: Review of adverse events, metabolism, and toxic dosages (2025)
• Experimental Dermatology — Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety (2019)
• PubMed — A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients (2008)
• PMC — Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis (2018)
• The Lancet — European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes (2004)
• PubMed — Theory and practice of nicotinamide trials in pre-type 1 diabetes (1996)
• PubMed — A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX, 2004)
• PubMed — The effect of niacinamide on osteoarthritis: a pilot study (1996)
• PMC — Niacinamide Antimicrobial Efficacy and Its Mode of Action via Microbial Cell Cycle Arrest (2024)
• PMC — Chronic Diarrhea and Alcoholism: Unravelling the Connection to Pellagra (2025)
• PMC — Steroid-Resistant Rash With Neuropsychiatric Deterioration: A Modern-Day Case of Pellagra (2025)
• Journal of Clinical Endocrinology & Metabolism — Effects of Nicotinamide Riboside on Endocrine Pancreatic Function in Nondiabetic Men With Obesity (2019)